Cryptococcal meningitis drug candidate, VT-1129, receives QIDP designation

The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to VT-1129, a novel candidate for the treatment of cryptococcal meningitis, according to the Durham, NC based company, Viamet Pharmaceuticals, Inc. Created under the Generating Antibiotics Incentives Now (GAIN) Act of 2012, QIDP designation provides Viamet with significant incentives for the ["]